IMM-0306S

阿沐瑞芙普α

Report date: 2026/03/06 20:02:51

Base Information

Drug NameIMM-0306S

Drug Alias NameIMM0306SIMM-0306S

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCluster of differentiation 47 inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAnti-CD20 +[4]

TargetsCluster of differentiation 47B-lymphocyte antigen CD20

Therapy Area/IndicationsLupus Erythematosus, Systemic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

Inactive CompaniesN/A

Active IndicationsLupus Erythematosus, Systemic

Inactive IndicationsN/A

Other Information

ATC CodeN/A